rTMS for Apathy Clinical Trial
Recruiting · NCT05561205 · Interventional (participants receive a specific treatment) · Lead sponsor: Sunnybrook Health Sciences Centre
View the official record on ClinicalTrials.gov →Interventions studied
methylphenidaterTMS
What this trial is about
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- mild or major neurocognitive disorder OR mild behavioural impairment
- Apathy for at least 4 weeks
- Stable dose of medication (\>4 weeks) that may affect cognition or behaviour
- Care partner who spends at least 10 hours a week with the subject
Exclusion criteria
- Current major depressive episode
- Agitation, delusions, hallucination
- Medical contraindications to rTMS
- Currently taking an amphetamine product
- Central nervous system abnormalities, Tourette's syndrome, or motor tics
- Current participation in another clinical trial
Where it is running
1 location listed.
- Sunnybrook Health Sciences Centre - Toronto, Ontario, Canada